Rocket


Overview
Financials
News + Filings
Key Docs
Charts
Ownership
Insiders


All
All (ex-4s)
10-K
10-Q
8-K
3,4,5
Proxy
Prospectus
Other
Tags
Appointed CFO
Quarterly results
Credit agrmnt [a]
CC transcript
Asset disposition
Acq. announced
Director departure
Appointed COO
Orthofix Medical Inc. (OFIX) Create: Alert

All | News | Filings
Date FiledTypeDescription
08/08/2023 8-K Investor presentation, Quarterly results
Docs: "Orthofix Reports Second Quarter 2023 Results and Raises Revenue and Adjusted EBITDA Guidance • Net sales of $187.0 million, an increase of 58% on a reported basis and 7% on a pro forma constant currency basis over prior year • Bone Growth Therapies growth of 10%, marking two consecutive quarters with double-digit net sales increases, with growth coming from both spine and fracture commercial channels • U.S. spinal implants, biologics, and enabling technologies sales up 7% over prior year on a pro forma basis, driven by new distribution and product innovation • Global Orthopedics net sales increase of 6% on a reported basis and 5% on a constant currency basis over prior year • Announced full commercial launch of the following products: o WaveForm® A interb...",
"Corporate Investor Deck August 2023 Forward Looking Statements This"
05/09/2023 8-K Quarterly results
Docs: "Orthofix Reports First Quarter 2023 Results • Net sales of $175.2 million, an increase of 65% on a reported basis and 12% on a pro forma constant currency basis over prior year • Bone Growth Therapies growth of 14%, with growth coming from both spine and fracture commercial channels • U.S. spinal implant sales up 18% over prior year on a pro forma basis, driven by new distribution and product innovation • Continued double-digit growth in Global Orthopedics over prior year on a constant currency basis • Announced the full commercial launch of the Lattus™ Lateral Access System and the Fathom™ Pedicle-Based Retractor System, which addresses an estimated $1.8 billion market related to minimally invasive spine procedures"
03/06/2023 8-K Quarterly results
Docs: "Orthofix Medical Reports Orthofix and SeaSpine Fourth Quarter and Full-Year 2022 Results LEWISVILLE, Texas — March 6, 2023 — The merger of Orthofix Medical Inc. and SeaSpine Holdings Corporation became effective as of January 5, 2023. This news release includes the financial results of stand-alone Orthofix and stand-alone SeaSpine for the fourth quarter and full year ended December 31, 2022. As such, these financial results do not include any potential accounting adjustments the merger may have on future net sales or operating results. Orthofix Fourth Quarter Highlights • Net sales of $122.2 million, a decrease of 2% on a reported basis and flat on a constant currency basis over prior year • Bone Growth Therapies net sales growth of approximately 3%, driven by the commercial ..."
11/03/2022 8-K Quarterly results
08/05/2022 8-K Quarterly results
05/06/2022 8-K Quarterly results
02/25/2022 8-K Quarterly results
11/05/2021 8-K Quarterly results
Docs: "Orthofix Reports Third Quarter 2021 Results"
08/06/2021 8-K Quarterly results
Docs: "Orthofix Reports Second Quarter 2021 Results"
02/26/2021 8-K Quarterly results
11/05/2020 8-K Quarterly results
Docs: "Net sales of $111.0 million, an increase of 52% sequentially and within 2% of our 2019 performance • US Spinal Implants third quarter net sales increased 19% over the prior year • Motion Preservation sales in the U.S. of $5.2 million, an increase of 44% sequentially and over 400% over prior year • Entered into an investment and co-development partnership with Neo Medical SA"
08/06/2020 8-K Quarterly results
05/08/2020 8-K Quarterly results
02/25/2020 8-K Quarterly results
10/28/2019 8-K Quarterly results
08/05/2019 8-K Quarterly results
Docs: "Jon Serbousek to succeed Brad Mason as President and Chief Executive Officer on November 1, 2019 • Net sales of $115.9 million, an increase of 3.9% compared to prior year and 5.0% on a constant currency basis • Biologics products net sales increased 14.2% and now has #1 market share position within its segment 1 • $500,000 in US M6-C cervical disc sales since June 1 • Company reiterates full year 2019 guidance"
05/06/2019 8-K Quarterly results
Docs: "Net sales of $109.1 million, an increase of 0.4% compared to prior year and 1.9% on a constant currency basis • Biologics products net sales increased 16.6% excluding the contractual reduction in marketing services fee • Net income of $0.9 million; compared to net income of $5.2 million in the prior year • Adjusted EBITDA of $15.7 million; a decrease of $4.1 million, or 20.5%, compared to prior year • Company reiterates full year 2019 guidance • First U.S. patients implanted with the M6-C™ artificial cervical disc following FDA approval • Initiated limited launch of fiberFUSE™, a differentiated demineralized bone matrix",
"Orthofix Recast of Historical Financial Results for Changes to Reportable Business Segments"
02/25/2019 8-K Quarterly results
10/29/2018 8-K Quarterly results
Docs: "Orthofix Reports Third Quarter 2018 Financial Results"
08/06/2018 8-K Quarterly results
Docs: "First Amended and Restated Credit Agreement, among Orthofix Holdings, Inc., Victory Medical Limited, Orthofix International B.V., Orthofix Medical Inc. and certain subsidiaries of Orthofix Medical Inc. as guarantors, the several banks and other financial institutions as may from time to time become parties thereunder as lenders, and JPMorgan Chase, N.A., as administrative agent",
"Amended and Restated Employment Contract, between Orthofix AG and Davide Bianchi",
"Orthofix Reports Second Quarter 2018 Financial Results"
04/30/2018 8-K Quarterly results
Docs: "Orthofix Reports First Quarter 2018 Financial Results Completes acquisition of Spinal Kinetics"
02/26/2018 8-K Quarterly results
Docs: "Orthofix International Reports Fourth Quarter and Fiscal 2017 Financial Results"
10/30/2017 8-K Quarterly results
08/07/2017 8-K Quarterly results
Docs: "Orthofix International Reports Second Quarter 2017 Financial Results"
05/04/2017 8-K Form 8-K - Current report
02/27/2017 8-K Form 8-K - Current report
10/31/2016 8-K Form 8-K - Current report
08/01/2016 8-K Form 8-K - Current report
04/28/2016 8-K Quarterly results
Docs: "Net sales of $98.7 million; an increase of 11.8% over prior year on a constant currency basis · Adjusted EBITDA of $15.5 million, or 15.7% of net sales, an increase of 83.6% over prior year · Company increases fiscal year 2016 guidance"
02/29/2016 8-K Quarterly results
Docs: "Orthofix International Reports Fourth Quarter and Fiscal 2015 Financial Results"
11/03/2015 8-K Quarterly results
Docs: "Third quarter net sales of $101.2 million; an increase of 4.1% over prior year on a constant currency basis · Adjusted EBITDA of $15.9 million, or 15.7% of net sales · Announces $75 million share repurchase plan"
08/04/2015 8-K Quarterly results
Docs: "Second quarter reported net sales of $101.0 million; an increase of 5.0% on a constant currency basis · Adjusted EBITDA of $17.2 million, or 17.1% of net sales · Company increases fiscal year 2015 guidance"
05/18/2015 8-K Quarterly results
Docs: "Orthofix International Reports First Quarter 2015 Financial Results"
04/29/2015 8-K Quarterly results
Docs: "Employment Agreement, effective as of April 24, 2015, by and between Orthofix Inc. and Doug Rice",
"Orthofix International Reports Fourth Quarter and Fiscal 2014 Financial Results Appoints Doug Rice as Chief Financial Officer"
  Next >>

Rocket Data Systems, Inc. © 2019 | Contact Us | Data Disclaimer | Terms of Use | Privacy